Porcine Myogenic factor 6 (MYF6) ELISA Kit | MyBioSource MBS7214838 product information

product summary

company name :

MyBioSource

product type :

ELISA/assay

product name :

Porcine Myogenic factor 6 (MYF6) ELISA Kit

catalog :

MBS7214838

quantity :

48-Strip-Wells

price :

440 USD

more info or order :

MyBioSource product webpage

image

image 1 :

product information

catalog number :

MBS7214838

products type :

ELISA Kit

products full name :

Porcine Myogenic factor 6 (MYF6) ELISA Kit

products short name :

[Myogenic factor 6 (MYF6)]

other names :

[myogenic factor 6; Myogenic factor 6; myogenic factor 6; muscle-specific regulatory factor 4; class C basic helix-loop-helix protein 4; myogenic factor 6 (herculin); Class C basic helix-loop-helix protein 4; bHLHc4; Muscle-specific regulatory factor 4]

products gene name :

[MYF6]

other gene names :

[MYF6; MYF6; CNM3; MRF4; myf-6; bHLHc4; BHLHC4; MRF4; Myf-6; bHLHc4]

uniprot entry name :

MYF6_HUMAN

reactivity :

Porcine

specificity :

This assay has high sensitivity and excellent specificity for detection of MXD1. No significant cross-reactivity or interference between MXD1 and analogues was observed. NOTE: Limited by current skills and knowledge, it is impossible for us to complete the cross-reactivity detection between MXD1 and all the analogues, therefore, cross reaction may still exist in some cases.

storage stability :

Store all reagents at 2-8 degree C.

image1 heading :

Typical Testing Data/Standard Curve (for reference only)

other info1 :

Samples: Serum, Plasma, Cell Culture Supernatants, Body Fluid And Tissue Homogenate. Assay Type: Quantitative Competitive. Sensitivity: 0.1 ng/mL.

products categories :

Epigenetics and Nuclear Signaling

products description :

Intended Uses: This MXD1 ELISA kit is a 1.5 hour solid-phase ELISA designed for the quantitative determination of RabbitMXD1. This ELISA kit for research use only, not for therapeutic or diagnostic applications!. Principle of the Assay: MXD1 ELISA kit applies the competitive enzyme immunoassay technique utilizing a polyclonal anti-MXD1 antibody and an MXD1-HRP conjugate. The assay sample and buffer are incubated together with MXD1-HRP conjugate in pre-coated plate for one hour. After the incubation period, the wells are decanted and washed five times. The wells are then incubated with a substrate for HRP enzyme. The product of the enzyme-substrate reaction forms a blue colored complex. Finally, a stop solution is added to stop the reaction, which will then turn the solution yellow. The intensity of color is measured spectrophotometrically at 450nm in a microplate reader. The intensity of the color is inversely proportional to the MXD1 concentration since MXD1 from samples and MXD1-HRP conjugate compete for the anti-MXD1 antibody binding site. Since the number of sites is limited, as more sites are occupied by MXD1 from the sample, fewer sites are left to bind MXD1-HRP conjugate. A standard curve is plotted relating the intensity of the color (O.D.) to the concentration of standards. The MXD1 concentration in each sample is interpolated from this standard curve.

ncbi gi num :

4505299

ncbi acc num :

NP_002460.1

ncbi gb acc num :

NM_002469.2

ncbi mol weight :

26,953 Da

ncbi pathways :

C-MYB Transcription Factor Network Pathway (138073); CDO In Myogenesis Pathway (160998); Developmental Biology Pathway (477129); Diurnally Regulated Genes With Circadian Orthologs Pathway (198813); Id Signaling Pathway (198871); Myogenesis Pathway (160997)

ncbi summary :

The protein encoded by this gene is a probable basic helix-loop-helix (bHLH) DNA binding protein involved in muscle differentiation. The encoded protein likely acts as a heterodimer with another bHLH protein. Defects in this gene are a cause of autosomal dominant centronuclear myopathy (ADCNM). [provided by RefSeq, May 2010]

uniprot summary :

Myf-6: Involved in muscle differentiation (myogenic factor). Induces fibroblasts to differentiate into myoblasts. Probable sequence specific DNA-binding protein. Defects in MYF6 may be a cause of centronuclear myopathy type 3 (CNM3). A congenital muscle disorder characterized by progressive muscular weakness and wasting involving mainly limb girdle, trunk, and neck muscles. It may also affect distal muscles. Weakness may be present during childhood or adolescence or may not become evident until the third decade of life. Ptosis is a frequent clinical feature. The most prominent histopathologic features include high frequency of centrally located nuclei in muscle fibers not secondary to regeneration, radial arrangement of sarcoplasmic strands around the central nuclei, and predominance and hypotrophy of type 1 fibers. Protein type: Transcription factor; DNA-binding. Chromosomal Location of Human Ortholog: 12q21. Cellular Component: nucleoplasm; nucleus. Molecular Function: RNA polymerase II transcription factor activity, enhancer binding; protein heterodimerization activity; transcription factor activity. Biological Process: regulation of transcription from RNA polymerase II promoter; transcription from RNA polymerase II promoter; somitogenesis; skeletal muscle development; muscle cell differentiation; positive regulation of skeletal muscle fiber development; muscle cell fate commitment; skeletal muscle regeneration; positive regulation of muscle cell differentiation; positive regulation of transcription from RNA polymerase II promoter; negative regulation of transcription, DNA-dependent; positive regulation of myoblast differentiation. Disease: Myopathy, Centronuclear, 3

size1 :

48-Strip-Wells

price1 :

440 USD

size2 :

96-Strip-Wells

price2 :

640

size3 :

5x96-Strip-Wells

price3 :

2895

size4 :

10x96-Strip-Wells

price4 :

5415

more info or order :

MyBioSource product webpage